404 related articles for article (PubMed ID: 32455818)
1. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.
D'Aguanno S; Del Bufalo D
Cells; 2020 May; 9(5):. PubMed ID: 32455818
[TBL] [Abstract][Full Text] [Related]
2. What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?
Brinkmann K; Ng AP; de Graaf CA; Strasser A
Cell Death Differ; 2022 Jun; 29(6):1079-1093. PubMed ID: 35388168
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
4. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
5. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamic simulations on an inhibitor of anti-apoptotic Bcl-2 proteins for insights into its interaction mechanism for anti-cancer activity.
Anantram A; Kundaikar H; Degani M; Prabhu A
J Biomol Struct Dyn; 2019 Aug; 37(12):3109-3121. PubMed ID: 30526410
[TBL] [Abstract][Full Text] [Related]
7. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
8. BCL-2 protein family: attractive targets for cancer therapy.
Kaloni D; Diepstraten ST; Strasser A; Kelly GL
Apoptosis; 2023 Feb; 28(1-2):20-38. PubMed ID: 36342579
[TBL] [Abstract][Full Text] [Related]
9. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
[TBL] [Abstract][Full Text] [Related]
10. Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.
Pal P; Zhang P; Poddar SK; Zheng G
Expert Opin Ther Pat; 2022 Sep; 32(9):1003-1026. PubMed ID: 35993382
[TBL] [Abstract][Full Text] [Related]
11. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
12. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
13. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
[TBL] [Abstract][Full Text] [Related]
14. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
15. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
Sarosiek KA; Letai A
FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
[TBL] [Abstract][Full Text] [Related]
16. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
17. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
18. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
19. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
20. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
